Shares of ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) were down 3.8% during mid-day trading on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares changed hands during trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Price Performance
The company has a debt-to-equity ratio of 108.33, a quick ratio of 1.30 and a current ratio of 0.51. The firm has a market cap of C$51.48 million, a PE ratio of -1.78 and a beta of 1.19. The stock has a fifty day simple moving average of C$6.00.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Five stocks we like better than ProMIS Neurosciences
- 3 Monster Growth Stocks to Buy Now
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- 3 Stocks to Consider Buying in October
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- How to Effectively Use the MarketBeat Ratings Screener
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
